Trimel Pharmaceuticals Corp  

(Public, CVE:JV.P)   Watch this stock  
Find more results for Gregory P Hawkins�
0.120
Delayed:   2:14PM EST
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.01 - 0.21
Open     -
Vol / Avg. 0.00/19,467.00
Mkt cap 1.20M
P/E     -
Div/yield     -
EPS -0.10
Shares     -
Beta     -
Inst. own     -
Jul 31, 2014
Q2 2014 Trimel Pharmaceuticals Corp Earnings Call
Jul 30, 2014
Q2 2014 Trimel Pharmaceuticals Corp Earnings Release
Jun 24, 2014
Trimel Pharmaceuticals Corp at JMP Securities Healthcare Conference
Jun 18, 2014
Trimel Pharmaceuticals Corp at Bloom Burton & Co Healthcare Investor Conference
Jun 12, 2014
Trimel Pharmaceuticals Corp Conference Call to Provide In-Depth Review of the TefinaT Phase II Study Results
Jun 12, 2014
Trimel Pharmaceuticals Corp Annual Shareholders Meeting
  

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -120.88% -141.87%
Return on average equity -186.22% -348.76%
CDP Score - -

Address

2488 Dunwin Dr
MISSISSAUGA, ON L5L 1J9
Canada
+1-416-6790771 (Phone)
+1-905-5691809 (Fax)

Website links

Description

Trimel Pharmaceuticals Corporation (Trimel) is a development-stage specialty pharmaceutical company. It is engaged in developing medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders. The Company holds the development and marketing rights to a bioadhesive intranasal gel drug delivery technology platform and owns a novel dry power drug delivery technology platform and is pursuing the development and application of these technologies to products that are in Phase II and Phase III clinical testing. These drug delivery platforms are a bioadhesive intranasal gel and a unit dose dry powder inhaler/nasal dispersion system. Trimel�s targeted indications include male hypogonadism (low testosterone or Low-T), female sexual dysfunction (anorgasmia), and respiratory disorders (asthma). In July 2014, the Company acquired from Shire plc, the Canadian rights for Estrace (17-beta estradiol).

Officers and directors

Ian O. Ihnatowycz Independent Chairman of the Board
Age: 60
Tom Rossi President, Chief Executive Officer, Secretary, Director
Kenneth G. Howling Chief Financial Officer
Matthew Hawkins Vice President - Legal Affairs, Corporate Secretary
Nathan Bryson Vice President - Scientific Affairs
Rolf K. Reininghaus Executive Director, Director
Stephen Robert Gregory Lead Independent Director
John B. Friedrichsen Independent Director
Age: 52
Matthew J. Pfeffer CPA Independent Director
Age: 56
Jeffrey D. Sherman Independent Director
Age: 56